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Abstract
Shigella sonnei (S. sonnei) is a non-motile, rod shape, clinically significant, Gram-negative bacterium. It is 
commonly associated with dysentery (shigellosis). Recently, resistance to third and fourth generation cephalosporins 
and fluoroquinolones has been reported in S. sonnei. In the present study, we assessed the effect of biofield treatment 
on phenotyping and genotyping characteristic of S. sonnei (ATCC 9290). The lyophilized samples of S. sonnei were 
divided in three groups (G): G-I (control, revived), G-II (treatment, revived), and G-III (treatment, lyophilized). All 
these groups (control and biofield treated) were analyzed against antimicrobial susceptibility, biochemical reactions, 
and biotype number. The 16S rDNA sequencing was carried out to establish the phylogenetic relationship of 
S. sonnei with different bacterial species. The treated cells of S. sonnei exhibited an alteration of 3.33%, 10%, 
and 23.33% of total 30 tested antimicrobials in susceptibility assay for G-II on day 5 and 10 and G-III on day 10, 
respectively as compared to control. The treated cells of S. sonnei showed a significant change of about 12.12%, 
12.12%, and 57.58% biochemical reactions out of 33 tests in treated groups of G-II on day 5 and 10 and G-III on 
day 10, respectively. The biotype number was also changed in treated samples of S. sonnei. Based on nucleotide 
homology sequences and phylogenetic analysis, the nearest homolog species of S. sonnei (GenBank Accession 
Number: EU009190) was identified as Shigella flexneri (EF643608). These results revealed that biofield treatment 
can prevent the absolute resistance in microbe against the existing antimicrobials. 
Keywords: Antimicrobial susceptibility; Biofield treatment; 16S 
rDNA gene sequencing; Shigella sonnei
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Introduction
Development of antimicrobial resistance in several microbes like 
bacteria, viruses, fungi, or in parasites has been reported globally in 
the recent few decades. Frequent and improper use of antimicrobial 
further accelerated the incidence of microbial resistance [1]. Shigella 
sonnei  (S. sonnei) is a rod shape, non-motile, facultative anaerobic 
Gram-negative and lactose-fermenting bacterium. S. sonnei  is 
associated with gastrointestinal tract (GIT) infection disease shigellosis 
in both developed and developing countries, where the sanitation is 
insufficient [2,3]. S. sonnei is usually transmitted by fecal-oral route, 
direct interpersonal contact, contaminated food, water, or uncooked 
food. Shigella infection is the third most common gastroenteritis after 
Salmonella and Campylobacter infection in the USA. Recently, S. 
sonnei has become the most prevalent species in the developed world. It 
is estimated to cause 80–165 million cases of disease and 600,000 deaths 
annually, worldwide [4]. The S. sonnei has been acquired resistant 
to commonly used antimicrobials like streptomycin, tetracycline, 
sulfonamide, trimethoprim, and ampicillin. Emergence of extended-
spectrum β-lactamases (ESBLs) in S. sonnei was also detected in Korea 
[2,5]. Therefore the multidrug therapy required to treat the infection 
cause by resistant strain of microbes. However, multiple drug therapy 
shows serious toxicity and associated adverse effects like neurotoxicity 
and nephrotoxicity [6]. Due to associated side effects and failure of 
drug therapy, an alternate treatment approach is required. Recently, an 
alternate treatment known as biofield energy is reported that inhibits 
the growth of bacterial cultures [7]. Biofield is an electromagnetic 
field that permeates and surrounds living organisms and referred as 
biologically produced electromagnetic and subtle energy field that 
provides regulatory and communication functions within the human 
organism [8]. Various internal physiological processes such as blood 
flow, brain and heart function etc. generates biofield. Researchers have 
attempted different biologic studies and effects of biofield on various 
biomolecules such as proteins, antibiotics [9], conformational change 
in DNA [10] etc. Thus, human has the ability to harness the energy 
from environment or universe and can transmit into any living or 
nonliving object(s) around the Globe. The objects always receive the 
energy and responding into useful way that is called biofield energy 
and the process is known as biofield treatment [11]. Mr. Mahendra 
Trivedi’s biofield treatment (The Trivedi Effect®) has renowned to alter 
the various physicochemical characteristics of metals and ceramics 
[11-17]. Quality and quantity of several agriculture products have 
been improved by several folds in the biofield treated plants [18-20] 
and growth and adaptation of the plant were also enhanced with the 
help of biofield treatment [21,22]. In addition, the biofield treatment 
has considerably altered the phenotype and biotype of the microbe and 
subsequently, the susceptibility to antimicrobials was also changed [23-
25]. 
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Based on the knowledge of existing literatures and considering 
the clinical significance of S. sonnei, we evaluated to see the impact 
of biofield treatment on antimicrobial susceptibility, biochemical 
reactions pattern, biotype number, and 16S rDNA gene sequencing of 
the microbe. 
Materials and Methods
Two lyophilized vials of S. sonnei [American Type Culture 
Collection (ATCC) 9290] were purchased from MicroBioLogics, Inc., 
USA. The microbial sample vials were stored as per the suggested 
storage conditions till further use. The antimicrobial susceptibility study, 
biochemical reactions pattern, and biotype number were evaluated by 
MicroScan Walk-Away® (Dade Behring Inc., West Sacramento, CA) 
through Negative Breakpoint Combo 30 (NBPC30) panel. The 16S 
rDNA sequencing was performed using Ultrapure Genomic DNA Prep 
Kit (Cat KT 83, Bangalore Genei, India).
Biofield treatment
The lyophilized strain of S. sonnei were divided into three groups 
(G) like G-I (control), G-II (treatment, revived), and G-III (treatment, 
lyophilized). G-I consider as control. No treatment was given. The 
treatment groups (II and III) were in sealed pack and handed over to Mr. 
Trivedi for biofield treatment under laboratory condition. Mr. Trivedi 
provided the treatment through his energy transmission process to 
the treated groups without touching the samples. Subsequently, group 
G-I and G-II were assessed on day 5 and 10; and G-III was assessed 
on day 10. After that, all groups were evaluated for an antimicrobial 
susceptibility, biochemical reactions pattern, and biotype number [25]. 
The 16S rDNA gene sequencing of S. sonnei was also carried out. 
Investigation of antimicrobial susceptibility of S. sonnei
The antimicrobial susceptibility of S. sonnei was evaluated with the 
help of automated instrument, MicroScan Walk-Away® using Negative 
Breakpoint Combo 30 (NBPC30) panel as per the manufactures 
instructions [26]. The minimum inhibitory concentration (MIC) 
and a qualitative susceptibility like resistant (R), intermediate 
(I), and susceptible (S) were determined by analyzing the lowest 
antimicrobial concentration showing microbial growth inhibition [25]. 
The antimicrobial sensitivity study was carried out using following 
30 antimicrobials such as amikacin, amoxicillin/K-clavulanate 
acid, ampicillin/sulbactam, ampicillin, aztreonam, cefazolin, 
cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, 
cefuroxime, cephalothin, chloramphenicol, ciprofloxacin, gatifloxacin 
, gentamicin, imipenem, levofloxacin, meropenem, moxifloxacin, 
nitrofurantoin, norfloxacin, piperacillin, tazobactam, tetracycline, 
ticarcillin, tobramycin, and trimethoprim/sulfamethoxazole. All these 
antimicrobials were procured from Sigma-Aldrich.
Biochemical studies
The biochemical reactions of S. sonnei were carried out using 
MicroScan Walk-Away® system where, interpretation of biochemical 
reactions for microbial identification of Gram-negative organisms 
resulted in high accuracy [27,28]. The biochemical reactions patterns 
of control and treated samples of S. sonnei were performed using the 
following 33 biochemicals such as acetamide, adonitol, arabinose, 
arginine, cetrimide, cephalothin, citrate, colistin, esculin hydrolysis, 
nitrofurantoin, glucose, hydrogen sulfide, indole, inositol, kanamycin, 
lysine, malonate, melibiose, nitrate, oxidation-fermentation, 
galactosidase, ornithine, oxidase, penicillin, raffinose, rhamnose, 
sorbitol, sucrose, tartrate, tryptophan deaminase, tobramycin, urea, 
and Voges-Proskauer. All these biochemicals were procured from 
Sigma-Aldrich.
Biotype number
The biotype number of S. sonnei was found out utilizing the 
MicroScan Walk-Away® processed panel data report, using biochemical 
reactions data [26].
16S rDNA gene sequencing
Genomic DNA was prepared from biofield treated S. sonnei cells 
using genomic purification Kit, as per the manufacturer’s instructions. 
Subsequently, the 16S rDNA gene (~1.5 kb) was amplified using 
universal forward primer 5'-AGAGTTTGATCCTGGC-3' and universal 
reverse primer 5'-GGTTACCTTGTTACGACTT-3'. Subsequently, 
the amplified products were resolved by gel electrophoresis on 1.0% 
agarose gel, stained with ethidium bromide, and then visualized under 
UV light in a gel documentation unit (BioRad Laboratories, USA). The 
PCR amplified fragment was purified from the agarose gel utilizing 
a DNA Gel Extraction Kit. The amplified product was sequenced 
on commercial basis from Bangalore Genei, India. The received 16S 
rDNA sequences data were aligned and compared with the sequences 
stored in Gene Bank database of National Center for Biotechnology 
Information (NCBI) using the algorithm BLASTn program. Finally, 
the multiple sequence alignment/phylogenetic tree was constructed 
with help of MEGA 3.1 software utilizing neighbor joining method 
[29,30].
Results
Antimicrobial susceptibility assay
The antimicrobial sensitivity data were reported in Table 1 and 
2. The result showed that the biofield treated S. sonnei exhibited a 
significant alteration in susceptibility assay of about 3.33% (G-II 
on day 5), 10% (G-II on day 10), and 23.33% (G-III on day 10) of 
total tested antimicrobials. The antimicrobials ampicillin, aztreonam, 
cefotaxime, ceftazidime, chloramphenicol, and tetracycline were 
converted from R → S; simultaneously more than 2 folds decreases 
in MIC values in lyophilized treated group G-III; cefotaxime showed 
a decrease in susceptibility from R → I in G-II on day 10. Besides, 
amoxicillin/K-clavulanate and ampicillin/sulbactam were converted 
from S → R in G-II and cefepime converted from I → S in G-III on 
day 10. 
Identification of S. sonnei by biochemical reactions 
The results of biochemical reactions of S. sonnei are presented in 
Table 3, which represent a significant alteration in biochemical reactions 
of about 12.12% (G-II on day 5 and 10), and 57.58% (G-III on day 10) 
of total tested biochemicals as compared to control. The biochemicals 
such as adonitol, cephalothin, citrate, colistin, esculin hydrolysis, 
hydrogen sulfide, kanamycin, lysine, malonate, melibiose, raffinose, 
sorbitol, sucrose, tobramycin, urea, and Voges-Proskauer were changed 
from positive (control) → negative reactions (treated) in G-III microbes. 
Additionally, arginine was converted from positive to negative reaction 
in entire treated groups. Nitrofurantoin was converted from positive to 
negative in G-II on day 5 and G-III on day 10 (Table 3). Tartrate was 
converted from positive to negative reaction in both G-II and G-III on 
day 10; and inositol and tryptophan deaminase were converted from 
negative to positive reaction in G-II on both days (Table 3). All the data 
were compared as compared to control. 
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As evidenced from Table 6, the lowest value of genetic distance 
from S. sonnei was 0.002 base substitutions per site. The nearest 
homolog genus-species of S. sonnei (Genbank accession number: 
EU009190) was determined by analyzing the 16S rDNA sequencing 
and phylogenetic tree, and found to be Shigella flexneri (Genbank 
Effect of biofield treatment on biotype number 
Biotype number of S. sonnie was determined on MicroScan Walk-
Away® processed panel. The result was demonstrated an alteration in 
biotype number of S. sonnie in the entire treated groups G-II and G-III 
(Table 4). However, the species (S. sonnei) was remained unchanged in 
the entire treated group. 
16S rDNA gene sequencing
The 16S rDNA sequence was determined in S. sonnei and shown 
in Figure 1. The alignment and comparison of the gene sequences 
were performed with the sequences stored in Gene Bank data base 
available from NCBI using the algorithm BLASTn program. As 
evidenced from nucleotides homology and phylogenetic analysis the 
sample 6A (S. sonnei) was identified as the same species (S. sonnei) 
with 99% identity of gene sequencing data. Ten bacterial species and 
S. sonnei were considered as Operational Taxonomic Units (OTUs) 
to facilitate the investigation of phylogenetic relationship of S. sonnei 
among other related species. Total 1500 base nucleotide of 16S rDNA 
gene sequences were compared by multiple alignments with the help 
of ClustalW in MEGA3.1 [30], and the data are shown in Table 5. 
S. No.
Antimicrobial
Control Treated 
G-I
G-II G-III 
Day-5 Day-10 Day-10
1 Amikacin R R R R
2 Amoxicillin/k- clavulanate S S R S
3 Ampicillin/sulbactam S I R S
4 Ampicillin R R R S
5 Aztreonam R R R S
6 Cefazolin I I I I 
7 Cefepime I I I S 
8 Cefotaxime R R I S 
9 Cefotetan R R R R
10 Cefoxitin R R R R
11 Ceftazidime R R R S 
12 Ceftriaxone S S S S
13 Cefuroxime R R R R
14 Cephalothin R R R R
15 Chloramphenicol R R R S 
16 Ciprofloxacin S S S S
17 Gatifloxacin S S S S
18 Gentamicin I I I I 
19 Imipenem S S S S
20 Levofloxacin S S S S
21 Meropenem S S S S
22 Moxifloxacin S S S S
23 Nitrofurantoin R R R R
24 Norfloxacin S S S S
25 Piperacillin S S S S
26 Piperacillin/tazobactam S S S S
27 Tetracycline R R R S 
28 Ticarcillin/k-clavulanate S S S S
29 Tobramycin R R R R
30 Trimethoprim/sulfamethoxazole S S S S
Table 1: Effect of biofield treatment on Shigella sonnei to antimicrobial susceptibility 
pattern of selected antimicrobials
G, stands for group; The control group G-I and G-II were accessed on day 5 and 
10; and G-III was accessed on day 10, after the biofield treatment; I, intermediate; 
S, susceptible; R, resistant.
S. No. Antimicrobial
Control Treated
G-I 
G-II G-III
Day-5 Day-10 Day-10
1 Amikacin >32 >32 >32 >32
2 Amoxicillin/k- clavulanate ≤8/4 ≤8/4  >16/8 ≤8/4
3 Ampicillin/sulbactam ≤8/4 16/8 >16/8 ≤8/4
4 Ampicillin >16 >16 >16 ≤8
5 Aztreonam >16 >16 >16 ≤8
6 Cefazolin 16 16 16 16
7 Cefepime 16 16 16 ≤8
8 Cefotaxime >32 >32 32 ≤16
9 Cefotetan >32 >32 >32 >32
10 Cefoxitin >16 >16 >16 >16
11 Ceftazidime >16 >16 >16 ≤8
12 Ceftriaxone ≤8 ≤8 ≤8 ≤8
13 Cefuroxime >16 >16 >16 >16
14 Cephalothin 16 16 16 16
15 Chloramphenicol >16 >16 >16 ≤8
16 Ciprofloxacin ≤1 ≤1 ≤1 ≤1
17 Gatifloxacin ≤2 ≤2 ≤2 ≤2
18 Gentamicin >8 >8 >8 >8
19 Imipenem ≤4 ≤4 ≤4 ≤4
20 Levofloxacin ≤2 ≤2 ≤2 ≤2
21 Meropenem ≤4 ≤4 ≤4 ≤4
22 Moxifloxacin ≤2 ≤2 ≤2 ≤2
23 Nitrofurantoin >64 >64 >64 >64
24 Norfloxacin ≤4 ≤4 ≤4 ≤4
25 Piperacillin ≤16 ≤16 ≤16 ≤16
26 Piperacillin/tazobactam ≤16 ≤16 ≤16 ≤16
27 Tetracycline >8 >8 >8 ≤4
28 Ticarcillin/k-clavulanate ≤16 ≤16 ≤16 ≤16
29 Tobramycin >8 >8 >8 >8
30 Trimethoprim/sulfamethoxazole ≤2/38 ≤2/38 ≤2/38 ≤2/38
G, stands for group; MIC data is presented in µg/mL 
Table 2: Effect of biofield treatment on Shigella sonnei to minimum inhibitory 
concentration (MIC) of selected antimicrobials. 
Figure 1: Phylogenetic tree of the partial 16S rDNA gene sequencing using 
MEGA 3.1 software by Neighbor joining method.
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accession number: EF643608). The distance matrix was prepared 
based on nucleotide sequence homology data and presented in 
Table 6. All pairwise distance analysis was carried out employing the 
p-distance method in MEGA3.1 software.
Discussion 
Antimicrobial resistance is a major global threat to public health, 
reported by World Health Organization (WHO). WHO also reported 
a post-antibiotic era, where people will die from simple microbial 
infections that have been curable for decades. Microbes naturally mutate 
and ultimately become immune to antimicrobials. Unfortunately, 
due to misuse of antimicrobials like over-prescribing by doctors or 
improper uses by patients is causing it to happen in much faster than 
expected. Similarly, S. sonnei has been acquired resistant to commonly 
used antimicrobials like tetracycline, streptomycin, trimethoprim, 
sulfonamide, and ampicillin. Further, emergence of extended-spectrum 
β-lactamases (ESBLs) was also detected in S. sonnei in some Asian 
countries like Korea [2,3,31]. 
Due to increasing the number of clinical specimens, cost-
effectiveness, and convenient interfaces with hospital information 
systems and laboratory the uses of automated or semi-automated 
systems for the susceptibility testing and identification of microbes 
has been increased recently [32]. Therefore, we also utilized the 
MicroScan Walk-Away® system for analysis of antimicrobial sensitivity, 
biochemical reactions, and biotyping. The overall result of antimicrobial 
susceptibility of biofield treated S. sonnei suggested that biofield 
treatment has significantly alerted the sensitivity of microbes in both 
side (either S → R or R → S) as compared to control. The biochemical 
reactions of treated cells of S. sonnei were altered in the range of 12.11 to 
57.58% in treated group as compared to control, which could be due to 
some alteration happened in metabolic enzyme systems and/or genetic 
system. It was also found that there was an alteration of biotype number 
in treated groups of S. sonnei. Based on the BLASTn analysis, the 
sample 6A was identified as S. sonnei. The closest homologues species of 
S. sonnei was identified as Shigella flexneri. The present study revealed 
that biofield treatment can alter the sensitivity of antimicrobials against 
S. sonnei. It seems that biofield treatment can play a potential role to 
circumvent the severe microbial infection in the fast and cost effective 
way as compared to modern medication. 
Conclusion 
Altogether data suggest that there was an impact of biofield 
treatment on antimicrobial susceptibility, biochemical reactions 
pattern, and biotype number of S. sonnei. To the best of our 
knowledge, this is the first report describing the significant impact 
of biofield treatment on S. sonnei in relation to change the sensitivity 
of antimicrobials. 
S. No. Code Biochemical 
Control Treated
G-I 
G-II G-III
Day-5 Day-10 Day-10
1 ACE Acetamide - - - -
2 ADO Adonitol + + + -
3 ARA Arabinose + + + +
4 ARG Arginine + - - -
5 CET Cetrimide - - - -
6 CF8 Cephalothin + + + -
7 CIT Citrate + + + -
8 CL4 Colistin + + + -
9 ESC Esculin hydrolysis + + + -
10 FD64 Nitrofurantoin + - + -
11 GLU Glucose + + + +
12 H2S Hydrogen sulfide + + + -
13 IND Indole - - - -
14 INO Inositol - + + -
15 K4 Kanamycin + + + -
16 LYS Lysine + + + -
17 MAL Malonate + + + -
18 MEL Melibiose + + + -
19 NIT Nitrate + + + +
20 OF/G Oxidation-fermentation/glucose + + + +
21 ONPG Galactosidase + + + +
22 ORN Ornithine + + + +
23 OXI Oxidase - - - -
24 P4 Penicillin + + + +
25 RAF Raffinose + + + -
26 RHA Rhamnose + + + +
27 SOR Sorbitol + + + -
28 SUC Sucrose + + + -
29 TAR Tartrate + + - -
30 TDA Tryptophan deaminase - + + -
31 TO4 Tobramycin + + + -
32 URE Urea + + + -
33 VP Voges-Proskauer + + + -
G, stands for group; -, (negative); +, (positive)
Table 3: Effect of biofield treatment on Shigella sonnie to biochemicals reactions 
pattern.
Feature
Control Treated
G-I
G-II G-III
Day-5 Day-10 Day-10
Biotype 7736 7376 7776 5776 7776 5776 4300 1010
Organism Identification Name S. sonnei S. sonnei S. sonnei S. sonnei
Table 4: Effect of biofield treatment on Shigella sonnei to alteration in biotype.
Alignment view AN
Alignment 
results Sequence description
6A 0.99 Sample studied
CP000948 0.99 Escherichia coli strain DH10B,
U00096 0.99 Escherichia coli strain K12 sub str. MG1655
EU009194 0.99 Shigella sonnei strain FBD020
EU009192 0.99 Shigella sonnei strain FBD018
EU009190 0.99 Shigella sonnei strain FBD016
EU009187 0.99 Shigella flexneri strain FBD002
EU009178 0.99 Shigella boydii strain FBD007
EF643608 0.99 Shigella flexneri strain FBD001shig
EU009183 0.99 Shigella dysenteriae strain FBD012
EU009177 0.99 Shigella boydii strain FBD006
AN: Accession Number
Table 5: The closest sequences of Shigella sonnei from sequence alignment using 
NCBI GenBank and Ribosomal database project (RDP).
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AN 1 2 3 4 5 6 7 8 9 10 11
EU009194 1 — 0.998 0.995 0.998 1.000 0.998 0.995 0.997 0.997 1.000 0.998
EU009187 2 0.002 — 0.994 0.999 0.998 0.999 0.994 0.999 0.999 0.998 0.997
U00096 3 0.005 0.006 — 0.994 0.995 0.994 1.000 0.993 0.993 0.995 0.994
EU009178 4 0.002 0.001 0.006 — 0.998 0.999 0.994 0.998 0.998 0.998 0.997
EU009192 5 0.000 0.002 0.005 0.002 — 0.998 0.995 0.997 0.997 1.000 0.998
EF643608 6 0.002 0.001 0.006 0.001 0.002 — 0.994 0.998 0.998 0.998 0.997
CP000948 7 0.005 0.006 0.000 0.006 0.005 0.006 — 0.993 0.993 0.995 0.994
EU009183 8 0.003 0.001 0.007 0.002 0.003 0.002 0.007 — 1.000 0.997 0.997
EU009177 9 0.003 0.001 0.007 0.002 0.003 0.002 0.007 0.000 — 0.997 0.997
EU009190 10 0.000 0.002 0.005 0.002 0.000 0.002 0.005 0.003 0.003 — 0.998
6A 11 0.002 0.003 0.006 0.003 0.002 0.003 0.006 0.003 0.003 0.002 —
AN: Accession Number
Table 6: Distance matrix based on nucleotide sequence homology (Using Kimura-2 Parameter).
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